The importance of the effect of underlying disease on rejection outcomes following orthotopic liver transplantation.
Despite major advances in immunopharmacology, virtually all patients receive the same center-specific immunosuppressive regimen following orthotopic liver transplantation (OLT). The present analysis was performed on the hypothesis that the original disease representing the indication for OLT leads to a different initial immunological situation of the patient. The type of original disease might therefore be a predisposing factor for acute rejection episodes and influence graft and patient survival. From January 1988 to July 1994, 34 patients received OLT at our institution for end-stage primary biliary cirrhosis (group 1) and 66 patients for end-stage alcoholic cirrhosis (group 2). Overall survivals at 1 and 5 years in group 1 versus group 2 were 67% versus 80% and 50% versus 68%, respectively (P<0.04). Retransplantation was performed in 21% of patients from group 1 and in 6% from group 2. The estimated risk for freedom from acute rejection amounts to 38% in group 1 compared with 59% in group 2 (P<0.02). Multivariate regression analysis of potential risk factors identified only the underlying disease as independent predictor. Analysis of cumulative rates of clinically relevant rejection episodes stratified by group revealed 0.29 and 0.05 episodes per patient at one month and 0.80 and 0.06 at six months (P<0.009) respectively. In our clinical experience it was possible to confirm the hypothesis that the underlying disease is the reason for a significantly different incidence of acute rejection episodes and that it subsequently influences graft and patient survival. This approach to an individually adapted immunosuppressive therapy should be taken into consideration and other appropriate parameters investigated.
Berlakovich
G A
GA
Department of Transplant Surgery, University of Vienna, Austria.
Imhof
M
M
Karner-Hanusch
J
J
Gotzinger
P
P
Gollackner
B
B
Gnant
M
M
Hanelt
S
S
Laufer
G
G
Muhlbacher
F
F
Steininger
R
R
D000208:Acute Disease; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000209:etiology; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology*; D006085:Graft Survival / Q000276:immunology; D006801:Humans; D008104:Liver Cirrhosis, Alcoholic / Q000276:immunology* / Q000601:surgery; D008105:Liver Cirrhosis, Biliary / Q000276:immunology* / Q000601:surgery; D016031:Liver Transplantation / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D014777:Virus Diseases / Q000209:etiology